Mark Rypien
  • Isracann Biosciences (IPOT) welcomes Super Bowl XXVI MVP and mental health advocate Mark Rypien to its advisory board
  • Mr. Rypien had a 13-year career in the NFL, and, as a result of sustained trauma during that time, Mark has suffered and continues to deal with some long-term effects
  • Mr. Rypien is partnering with the Praesidio team to bring awareness to mental health and the potential of Praesidio products as part of a treatment regimen
  • Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer/distributor
  • Isracann Biosciences Inc. (IPOT) opened trading at C$0.045

Isracann Biosciences (IPOT) welcomes Super Bowl XXVI MVP and mental health advocate Mark Rypien to its advisory board.

Isracann CEO Phil Floucault commented on the appointment.

“Mr. Rypien had a distinguished 13-year career in the NFL during which he was named to the All Madden Team in 1992, twice named to the Pro Bowl (1988 and 1991) and the first and only Canadian born Super Bowl MVP. As is widely reported and, as a result of sustained trauma during that time, Mark has suffered and continues to deal with some long-term effects. It is his advocacy for other athletes, military and civilians that brought us together. We see a synergy of working together to provide access to mental health support and to improve the mental health of all people. Whether it be our military and civilians or our athletes both professional and amateur.”

Isracann recently acquired Praesidio Health, a Canadian medical research company that develops and validates natural health products using an evidence-based process. Included in the first round of formulations submitted to Health Canada for approval is a product dubbed, “Quiet Peace.”

“The trauma that I sustained from my career definitely effected my mental health,” says Mark. “Back then, there were no concussion protocols. You just shook it off and kept playing. I have carried those tackles with me long after I retired. During a particularly low point in my mental wellbeing, I attempted suicide. That was a wake-up call for me. I had had enough of feeling this way. It was time to start talking about mental health.”

Since then, Mark has become an advocate for athletic mental health and the mental health of our military and civilians.

“I’m excited to work with the Praesidio team to bring awareness to mental health and the potential that Praesidio products bring as part of a treatment regimen. The issues that I have dealt with and am continuing to deal with are faced by many professional athletes, military, and civilians alike. I am looking forward to helping support them,” says Mark.

Isracann is a cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm.

Isracann Biosciences Inc. (IPOT) opened trading at C$0.045.


More From The Market Online

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends

Avicanna completes topical gel study

Avicanna (TSX:AVCN) has completed its observational real-world evidence study of its RHO Phyto branded cannabigerol gel.